Closing the Cardiovascular Site Gap:
Intelligence Meets Site Expansion
Earn a Certificate of Live Attendance
AI Webinar Explorer available after event
About this webinar
Cardiovascular trials are becoming harder to execute. Patient populations increasingly overlap across competing studies and sponsors who rely on the same historically top-performing sites face diminishing returns as those sites reach capacity, fatigue or age out of the pipeline.
This webinar examines how cardiovascular trial delivery is evolving from a CRO perspective. Fortrea will introduce its new Feasibility Intelligence Engine (FIE), which brings together historical experience, internal trial history and external datasets into a single, unified platform, giving teams one consolidated source of truth to identify patterns, estimate patient populations and prioritize the strongest countries and sites. For sponsors, this means faster proposal turnaround, sharper country and site prioritization, real-time scenario modeling and a meaningfully reduced risk of under-enrollment, giving them a clearer, faster path from protocol to study start.
FIE’s depth of trial and real-world data provides sponsors with a sharper view of their existing site landscape and that same intelligence becomes even more powerful when paired with an actively expanding, on-the-ground site network. Dan Robitaille from Velocity, a diversified site partner working across many therapeutic areas, will share how new and non-traditional sites, particularly those with strong patient access, are identified and developed to become trial-ready, expanding the pool of sites sponsors can draw on.
Through operational and strategic lenses, the speakers will discuss how pairing trial intelligence with an actively growing site network addresses two needs at once: sharper decisions on the sites already in play today and a broader, more diverse pool for tomorrow’s studies.
Designed for biotech and biopharma teams managing complex, competitive cardiovascular programs, this session brings both perspectives together to address what it actually takes to keep a cardiovascular site pool healthy, without losing time, quality or sponsor confidence.
Register for this webinar to learn how combining feasibility intelligence with site expansion can strengthen site selection, reduce enrollment risks and improve cardiovascular trials.
Who should attend
- Biopharma and Biotech Sponsors
- Clinical Development leaders
- Portfolio and Program Leads
- Clinical Operations leaders
- Feasibility and Site Strategy teams
- Study Start-Up professionals
- Patient Recruitment Leads
- Site Partners and Alliance teams
- Outsourcing and Vendor Strategy leaders
- Data Science and Innovation teams
- Investigators and Site Directors
What you will learn
- Recognize the risks of relying on the same historically top-performing cardiovascular sites and what diminishing returns mean for delivery timelines
- Understand how Fortrea’s Feasibility Intelligence Engine (FIE) strengthens study feasibility, from faster proposal turnaround and protocol design support to sharper country and site prioritization
- Connect intelligence-driven site selection with an expanding site network to achieve faster site identification and more predictable enrollment
- Identify high-potential, non-traditional sites with strong patient access that can be developed into trial-ready partners
- Apply practical approaches to diversifying and future-proofing a cardiovascular site pool, rather than repeatedly returning to the same sites
- Evaluate what a combined intelligence-plus-partner model means for study start-up timelines and sponsor decision-making
Featured Speakers
JB Flinders, PhD, MBA
With 20 years of clinical and academic trial experience, JB’s focus is advancing the design, feasibility and operational execution of Phase I-IV clinical trials across a broad range of therapeutic areas, with particular emphasis on rare and complex diseases. Across global CRO leadership roles, he has directed strategic development for more than 500 clinical proposals and subsequent awarded studies, with a deep familiarity of the full evidence lifecycle from protocol conception and endpoint alignment, feasibility and analytics, site and vendor relationships, study conduct and commercialization strategies.
JB is also the Co-Founder of Decentra Health, building federated rare disease registry infrastructure and privacy-preserving data-sharing models that support longitudinal research, natural history studies and decentralized trial readiness. These efforts emphasize interoperability, patient-owned data frameworks, cross-study harmonization and scalable global collaboration without requiring centralized data ownership. His belief is that ethically grounded data ecosystems can support both scientific advancement and patient trust.
James Joyce
With more than 20 years of experience in pharmaceutical research and clinical development and over 15 years of leadership experience within the organization, based in Atlanta, Georgia, James leads Phase I-III global clinical development portfolios. His strengths lie in program and project management, governance, alliance collaboration, regulatory inspection readiness, commercial strategy and client engagement. Throughout his career, he has successfully managed large multinational clinical programs in cardiovascular, metabolic, endocrine and other therapeutic areas, while building trusted relationships with executive stakeholders, sponsors, vendors and regulatory authorities including the FDA and EMA.
Prior to Fortrea, James held clinical program leadership roles at AbbVie and Solvay Pharmaceuticals and developed foundational experience in clinical operations, inspection readiness and supply management. Recognized for his strengths in strategic portfolio leadership, business development, budget negotiations and global program delivery, he is committed to advancing enterprise-wide clinical development strategies, strengthening strategic collaborations and driving innovation in global clinical trial execution.
Carlos Zaccarelli Filho
Carlos Zaccarelli Filho is a seasoned leader in clinical research strategy and feasibility, with over 20 years of experience across global CROs and biopharmaceutical organizations. Currently serving as Director, Feasibility Intelligence & Forecasting at Fortrea, he oversees global feasibility operations, data-driven site identification and risk management strategies.
Across global CRO roles, he built and mentored experienced teams, expanded operations into new markets and drove innovation in feasibility intelligence tools. His therapeutic experience spans oncology, immunology, neuroscience, infectious diseases and cardiometabolic disorders, with hands-on involvement in all phases of clinical trials.
Carlos combines scientific rigor with strategic insight, contributing to publications in ophthalmology and HIV research and is recognized for advancing data-driven recruitment strategies and global site feasibility in complex therapeutic areas.
Dan Robitaille
Dan Robitaille is Vice President of Business Development at Velocity Clinical Research. Having started his career as a Clinical Research Coordinator, Dan brings a unique perspective shaped by firsthand experience managing studies at the site level and years of partnering with sponsors to advance drug development programs.
With over 20 years of experience in clinical research, he works with pharmaceutical, biotechnology and CRO organizations to develop patient-centric enrolment strategies, optimize site identification, selection and accelerate study delivery. His site experience spans CNS, infectious disease, endocrinology, metabolism and others with a focus on leveraging integrated site networks to improve execution, enrolment and patient access. Dan is a frequent advisor to sponsors on feasibility, operational strategy and successful trial delivery across North America and Europe.
Partner for this event
Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X.